Ezabenlimab

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, China
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan

and more 1 locations

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1

Recruiting

Conditions: Neuroendocrine Neoplasms
Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: Obrixtamig
Drug: Ezabenlimab

First Posted Date: 2023-05-30

Last Posted Date: 2024-12-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT05879978

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
🇫🇷
HOP Louis Pradel, Bron, France
🇧🇪
UNIV UZ Gent, Gent, Belgium

and more 5 locations

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: VSV-GP154
Drug: ATP150
Drug: ATP152
Drug: Ezabenlimab

First Posted Date: 2023-05-06

Last Posted Date: 2024-10-09

Lead Sponsor: Amal Therapeutics

Target Recruit Count: 85

Registration Number: NCT05846516

Locations: 🇺🇸
USC/Norris Comprehensive Center, Los Angeles, California, United States
🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 12 locations

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: BI 1703880
Drug: Ezabenlimab

First Posted Date: 2022-07-25

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT05471856

Locations: 🇯🇵
Saitama Medical University International Medical Center, Saitama, Hidaka, Japan
🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇪🇸
Instituto Valenciano de Oncología, Valencia, Spain

and more 10 locations

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: BI 765063
Drug: Ezabenlimab
Drug: Pembrolizumab

First Posted Date: 2022-07-06

Last Posted Date: 2023-12-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2

Registration Number: NCT05446129

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: BI 770371
Drug: ezabenlimab

First Posted Date: 2022-04-14

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT05327946

Locations: 🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇨🇦
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada

and more 2 locations

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: BI 765063
Drug: Ezabenlimab
Drug: Cetuximab
Other: Investigator´s Choice Chemotherapy
Drug: BI 836880

First Posted Date: 2022-02-21

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT05249426

Locations: 🇯🇵
Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 21 locations

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Phase 1

Recruiting

Conditions: Carcinoma, Squamous Cell of Head and Neck (HNSCC)
Melanoma
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Ezabenlimab
Drug: BI 765063
Drug: BI 770371
Drug: [89Zr]Zr- BI 765063
Drug: [89Zr]Zr- BI 770371

First Posted Date: 2021-10-05

Last Posted Date: 2024-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT05068102

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: BI 765179
Drug: Ezabenlimab
Drug: Pembrolizumab

First Posted Date: 2021-07-12

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 160

Registration Number: NCT04958239

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇮🇹
Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Italy
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy